一名患有心源性栓塞性中风的孕妇静脉注射重组组织型纤溶酶原激活剂。
Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke.
作者信息
Wiese Kathleen M, Talkad Arun, Mathews Maureen, Wang David
机构信息
Department of Neurology, University of Illinois at Peoria, OSF St. Francis Medical Center, 530 NE Glen Oak Ave, Peoria, IL 61637, USA.
出版信息
Stroke. 2006 Aug;37(8):2168-9. doi: 10.1161/01.STR.0000230286.95513.c2. Epub 2006 Jun 22.
BACKGROUND AND PURPOSE
Historically, the use of tissue plasminogen activator (tPA) thrombolysis in pregnancy has been regarded as relatively contraindicated. Underlying this stance has been the concern over the risk of bleeding complications in both mother and child.
SUMMARY OF CASE
We report the successful use of intravenous recombinant tPA (rtPA) thrombolysis in a pregnant woman with acute cardioembolic stroke.
CONCLUSIONS
The patient improved clinically, did not develop complications after receiving rtPA, and at 37 weeks' gestation, delivered a healthy infant, demonstrating that rtPA thrombolysis may be used safely in pregnant women.
背景与目的
在历史上，妊娠期间使用组织型纤溶酶原激活剂（tPA）进行溶栓一直被视为相对禁忌。这一立场的背后是对母婴出血并发症风险的担忧。
病例摘要
我们报告了一名患有急性心源性脑栓塞性卒中的孕妇成功接受静脉注射重组tPA（rtPA）溶栓治疗的病例。
结论
该患者临床症状改善，接受rtPA治疗后未出现并发症，在妊娠37周时分娩出一名健康婴儿，表明rtPA溶栓治疗可在孕妇中安全使用。
Zotero 插件